Top > Search of International Patents > MEDICINAL COMPOSITION

MEDICINAL COMPOSITION NEW_EN

Foreign code F190009988
File No. (S2018-0494-N0)
Posted date Oct 28, 2019
Country WIPO
International application number 2019JP012429
International publication number WO 2019188950
Date of international filing Mar 25, 2019
Date of international publication Oct 3, 2019
Priority data
  • P2018-058171 (Mar 26, 2018) JP
Title MEDICINAL COMPOSITION NEW_EN
Abstract A medicinal composition for treating a central neurodegenerative disease, said medicinal composition comprising at least one member selected from the group consisting of nicotine, nobiletin, sinensetin and Nchinpi, characterized in that the central neurodegenerative disease is associated with mitochondrial dysfunction.
Outline of related art and contending technology BACKGROUND ART
Mitochondrial ATP stable supply of the maintenance functions of the system, to be essential for cell viability. Therefore, many eukaryotic ATP in a cell of the stable supply system failure, i.e. failure of mitochondrial function can be a definitive cause cell death. For example, 2 known as a large central neurodegenerative disease is Alzheimer's disease and Parkinson's disease (AD) (PD) is, the onset of cell death of neuronal cells cause an known.
In this case, neurons or nerve axons and dendrites of the morphological structure and the like in order to maintain the indispensable and the actin cytoskeleton, actin depolymerization-ATP consumption polymerization cycle, the total energy consumption of up to 1-50% of the brain are estimated (non-patent document 1, 2). Therefore, in the nerve cells in the brain, brain ATP balance does not fail in such a stable supply of the ATP system may be built.
On the other hand, V-1 (also called Myotrophin.) Is a protein, and protein , V-1 is human, 118 amino acids. V-1 is, in the molecule through the ankyrin binding protein actin capping protein (CP, CapZ). The CP, and coupled to the end of the actin filament, where the polymerization of actin by blocking the suppressed. V-1 is, the actin capping activity, thereby, promoting the formation of the actin cytoskeleton has been known (Non-Patent Document 3).
However, V-1 mitochondria function, is not known.
Shinensechin, nobiletin is, as can be included in the skin of tough genus (Citrus) and poly methoxy flavonoid, citrus unshiu peel (nobilis) is, in the mature of the mandarin orange satsuma mandarin or pericarp. Nobiletin shinensechin and is, has an effect of an anti-dementia has been known. Also, the citrus unshiu peel, herbal a longer used. However, any of the functions of the mitochondria, has not been known. Nicotine, mainly leaf tobacco alkaloids Nicotiana tabacum a kind of included. Smoking risk of Parkinson's disease that is known to reduce the systematic reviews (non-patent document 4). However, the nicotine mitochondria function, is not known.
Scope of claims (In Japanese)[請求項1]
 ニコチン、ノビレチン、シネセチン、及びチンピからなる群より選ばれる少なくとも1つを含む、中枢神経変性疾患の処置のための医薬組成物であって、前記中枢神経変性疾患が、ミトコンドリアの機能不全を伴うことを特徴とする、前記医薬組成物。

[請求項2]
 前記中枢神経変性疾患が、ミトコンドリアの機能不全を伴うアルツハイマー病、ミトコンドリアの機能不全を伴うパーキンソン病又はミトコンドリアの機能不全を伴う脳血管認知症である、請求項1に記載の医薬組成物。

[請求項3]
 前記処置が、V-1タンパク質とアクチンキャッピングタンパク質の複合体の形成の促進である、請求項2に記載の医薬組成物。

[請求項4]
 ミトコンドリアの機能不全の処置における使用のための、ニコチン、ノビレチン、シネセチン、及びチンピからなる群より選ばれる少なくとも1つの化合物。

[請求項5]
 前記ミトコンドリアの機能不全が、ミトコンドリアの機能不全を伴うアルツハイマー病、ミトコンドリアの機能不全を伴うパーキンソン病又はミトコンドリアの機能不全を伴う脳血管認知症である、請求項4に記載の化合物。

[請求項6]
 前記処置が、V-1タンパク質とアクチンキャッピングタンパク質の複合体の形成の促進である、請求項5に記載の化合物。

[請求項7]
 被験物質を神経細胞と接触させること、
 被験物質と接触した神経細胞におけるV-1タンパク質とアクチンキャッピングタンパク質との複合体のレベル及び/又はCOX Iの発現レベルを決定すること、
 決定されたレベル及び/又は発現レベルが、被験物質と接触していない神経細胞におけるV-1タンパク質とアクチンキャッピングタンパク質との複合体のレベル及び/又はCOX Iの発現レベルと比べて高いときに、被験物質をミトコンドリアの恒常性維持・強化に有用な候補物質として選択すること、
を含む、ミトコンドリアの恒常性の維持及び/又は強化に有用な候補物質のスクリーニング方法。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • TOHOKU UNIVERSITY
  • Inventor
  • YAMAKUNI, Tohru
  • KAWAHATA, Ichiro
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close